


group or nitro group,] X indicates a halogen atom, and Z indicates a halogen atom, piperazino group, N-methylpiperazino group, 3-methylpiperazino group, 3-hydroxypyrrolidino group, or pyrrolidino group of the following formula,



where, n is 0 or 1, R<sup>3</sup> indicates a [hydrogen atom or] lower alkyl group, R<sup>4</sup> indicates a hydrogen atom, lower alkyl group, hydroxy-substituted lower alkyl group or halogenated lower alkyl group and R<sup>5</sup> indicates a hydrogen atom, lower alkyl group, acyl group or alkoxy carbonyl group, the hydrates or the pharmaceutically acceptable acid addition or alkali salts thereof.

Please amend Claim 12 to correct the spelling of "pyrrolidiyl" to --pyrrolidiny--.

Please cancel Claims 11 and 14 through 18.

#### REMARKS

Claims 1 and 12 have been amended and Claims 11 and 14 through 18 have been canceled from this application. Reconsideration is respectfully requested.

The Examiner has rejected Claims 1 and 18 through 20 as being anticipated by Domagala. This rejection is respectfully traversed for the claims as presently amended.

Domagala requires in the 5-position the presence of an amino group, and ether group or a hydroxyl group as taught on Column 2, at lines 10 through 45. Claim 1 has been amended to recite only compounds which are unsubstituted at the 5-position, that is, that  $R^2$  is a hydrogen atom. Further, those species claims wherein the 5-position can be an amino group have been canceled, Claim 17 and 18. On the other hand, Claims 19 and 20 which were rejected are unsubstituted in the 5-position. Both in the generic formula on column 2 and in the specific compounds listed in columns 31 and 37 referred to by the Examiner, the presence of a substituent at the 5-position is required. In the species described in columns 31 and 37, the 5-position is substituted by an amino group, a group conspicuous by its absence from Claims 19 and 20. In the Office Action, the Examiner has acknowledged that other similar compounds not substituted in the 5-position are patentable over Domagala. It is assumed that reference to Claims 19 and 20 was in error and should have been referenced to Claims 17 and 18 which have been canceled. Since Domagala requires the 5-position to be substituted, no anticipation can exist for compounds which are unsubstituted in the 5-position. Furthermore, there is nothing in the Domagala reference which would lead the artisan to eliminate a substituent at the 5-position. Accordingly, it is respectfully submitted that the claims as now amended are patentable over the Domagala patent.


In addition, applicants have further amended Claim 1 and

canceled Claims 11 and 14 through 16 to provide unity of invention,  
i.e., limit the claims to disubstituted pyrrolidinyl.

In summary, Claims 1, 8 through 10, 12, 13, 19 and 20 remain  
in this application and are believed in condition for allowance.  
Early notice to this effect is respectfully requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



Richard D. Kelly  
Registration No. 27,757

1755 Jefferson Davis Hwy.  
4th Floor  
Arlington, Virginia 22202  
(703) 521-5940